OCT 23·SEC EDGARLow
Equels Thomas K purchased $5K of AIM
Equels Thomas K (CEO & President) purchased 31,250 shares of AIM ImmunoTech Inc. (AIM) at $0.16 on 2026-10-22.
StockNYSE · US · USDHealthcare · Biotechnology
$AIM
AIM ImmunoTech Inc.
Price · $AIMvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $AIM in the last 7 days.
Insider · 30dAll trades →
- Buys
- $5K 1 txs
- Sells
- — 0 txs
Equels Thomas K1× · $5K
10b5-1 share of filings0%
Top stories · $AIMMore →
OCT 7·stocktitan.net
Exploratory data found 34.8 months’ median survival in 39 patients with a low blood-cell ratio.
AIM ImmunoTech highlighted exploratory data showing 34.8 months' median survival in 39 pancreatic cancer patients with low neutrophil-to-lymphocyte ratio. Final dosing is complete in the DURIPANC trial with AstraZeneca's Imfinzi, but endpoint reporting is pending. The company is pursuing further clinical development and partnerships for a Phase 3 study.
OCT 1·tradingview.com
AIM ImmunoTech Inc. (AIM) Completes Final Ampligen Dosing in DURIPANC; Topline Data Expected 1Q27
AIM ImmunoTech completed final dosing in its Phase 2 DURIPANC trial for pancreatic cancer, with topline data expected in Q1 2027. The company also reported encouraging findings from a Netherlands Named Patient Program.
AIM sentiment & insider activity
Recent AIM coverage spans insider activity, financial news and corporate actions.
In the last 30 days, AIM insiders filed 1 SEC Form 4 transaction — 1 purchase ($5K) and no sales. The most active reporter was Equels Thomas K, CEO & President, with 1 filing.
What's driving AIM
Insider purchase may create modest bullish sentiment.
The data suggests potential efficacy of Ampligen as a maintenance therapy, which could lift sentiment but uncertainty remains until trial endpoints are reported.
The dosing completion is a catalyst that could drive the stock higher if the upcoming data are positive.
Positive clinical signals could boost investor sentiment and drive short‑term price appreciation if data are validated.
Small insider buy signals modest confidence but limited price impact.
AlphAI scores every news story that mentions AIM with an AI model for sentiment and relevance, and aggregates insider trades from AIM ImmunoTech Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $AIM
Score
Equels Thomas K purchased $5K of AIM
Equels Thomas K (CEO & President) purchased 31,250 shares of AIM ImmunoTech Inc. (AIM) at $0.16 on 2026-10-22.
1 min readExploratory data found 34.8 months’ median survival in 39 patients with a low blood-cell ratio.
AIM ImmunoTech highlighted exploratory data showing 34.8 months' median survival in 39 pancreatic cancer patients with low neutrophil-to-lymphocyte ratio. Final dosing is complete in the DURIPANC trial with AstraZeneca's Imfinzi, but endpoint reporting is pending. The company is pursuing further clinical development and partnerships for a Phase 3 study.
2 min read
AIM ImmunoTech Inc. (AIM) Completes Final Ampligen Dosing in DURIPANC; Topline Data Expected 1Q27
AIM ImmunoTech completed final dosing in its Phase 2 DURIPANC trial for pancreatic cancer, with topline data expected in Q1 2027. The company also reported encouraging findings from a Netherlands Named Patient Program.
1 min read
AIM ImmunoTech Highlights Ampligen’s Potential Role in the Evolving Pancreatic Cancer Treatment Landscape Following FDA Approval of Revolution Medicines’ Daraxonrasib
AIM ImmunoTech Inc. (AIM) highlighted Ampligen's potential in pancreatic cancer treatment following FDA approval of Revolution Medicines' daraxonrasib. CEO Thomas Equels outlined Ampligen's differentiated mechanism and clinical potential, citing median overall survival of 34.8 months in a selected patient population versus 12.5 months in historical controls.
2 min readEquels Thomas K purchased $5K of AIM
Equels Thomas K (CEO & President) purchased 24,000 shares of AIM ImmunoTech Inc. (AIM) at $0.21 on 2026-09-17.
1 min readEquels Thomas K purchased $2K of AIM
Equels Thomas K (CEO & President) purchased 11,000 shares of AIM ImmunoTech Inc. (AIM) at $0.21 on 2026-09-16.
1 min readEquels Thomas K purchased $5K of AIM
Equels Thomas K (CEO & President) purchased 22,000 shares of AIM ImmunoTech Inc. (AIM) at $0.22 on 2026-09-15.
1 min readEquels Thomas K purchased $1K of AIM
Equels Thomas K (CEO & President) purchased 5,900 shares of AIM ImmunoTech Inc. (AIM) at $0.22 on 2026-09-14.
1 min readAIM ImmunoTech Inc. (AIM): Entry into a Material Definitive Agreement
AIM ImmunoTech Inc. (AIM) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. From September 8, 2026 to September 9, 2026, AIM ImmunoTech Inc. (the “Company”) entered into a total of two exchange agreements (the “Exchange Agreements”) and, for each, a corresponding partitioned promissory note (together,
1 min readAIM ImmunoTech Inc. (AIM): Entry into a Material Definitive Agreement
AIM ImmunoTech Inc. (AIM) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On September 3, 2026 and September 4, 2026, AIM ImmunoTech Inc. (the “Company”) entered into a total of two exchange agreements (the “Exchange Agreements”) and, for each, a corresponding partitioned promissory note (together,
1 min read